Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World…
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year…
SOUTHLAKE, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Renewal Fuels, Inc. (OTC: RNWF) (“RNWF”, “American Fusion” or the “Company”), today…
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 March 09, 2026 10:21 ET…
BEIJING, March 4, 2026 /PRNewswire/ -- As China's annual Two Sessions gets underway, CGTN published an article analyzing how the country…
Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting…
February 24, 2026 16:30 ET | Source: Cardiff Oncology, Inc. Reported positive update from Phase 2 CRDF-004 trial in first-line…
February 13, 2026 16:30 ET | Source: Inotiv, Inc. WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc.…
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public…
SINGAPORE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phaos Technology Holdings (Cayman) Limited, (NYSE American: POAS), (“the Company”), an advanced microscopy…